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A solution mediated transformation between two co-crystal 
phases has been observed for the p-5 
toluensulfonamide/triphenylphosphine oxide co-crystal 
system. This system has two known co-crystals with 1:1 and 
3:2 stoichiometry respectively, and the ternary phase diagram 
(TPD) for the system has been determined in acetonitrile 
previously. By manipulating the solution composition in this 10 
solvent to a region of the TPD where the 1:1 co-crystal is 
stable, the 3:2 co-crystal could be observed to convert to the 
1:1 co-crystal. The corresponding transformation was true 
for the 1:1 co-crystal in a region of the TPD where the 3:2 co-
crystal is stable; the 1:1 co-crystal converted to the 3:2 co-15 
crystal.  
 
The creation of co-crystals has recently gained increased interest 
within the solid-state community as a route for the modification 
of the physico-chemical properties of active pharmaceutical 20 
ingredients (APIs).1-5 While the creation of such materials has 
been repeatedly demonstrated, studies into the crystallisation 
processes and transformations between such materials has only 
recently received attention.6-17 However, such understanding is 
required to fully develop suitable crystallisation processes for the 25 
industrial synthesis of pharmaceutical co-crystals. 
 The key source of information for the design of a solution-
based co-crystallisation is the ternary phase diagram (TPD), 
which indicates the thermodynamically stable phase for a given 
composition.6 While previous studies have, in general, focused on 30 
the development of methodologies for the construction of TPDs 
and their application in the growth of a stable phase, less work 
has been carried out on the kinetics of the crystallisation and 
influence of conditions on the growth of the differing phases. The 
solution mediated transformation between polymorphic co-35 
crystals has been reported for the carbamazepine/isonicotinamide 
system.18 The carbamazepine/nicotinamide system has been 
investigated to study both the competing crystallisation kinetics 
of the differing phases in regions where two solid phases are 
stable11 and the solution mediated transformation from 40 
carbamazepine to the co-crystal through the introduction of 
enough solid nicotinamide to shift the composition into a 
different region of the TPD.14 In the carbamazepine/nicotinamide 
system only a single co-crystal phase is known and so only the 
conversion between the starting materials and the co-crystal are 45 
possible. While a number of systems exhibit co-crystals of 
differing stoichiometry and the identification of the regions of the 
TPD where the differing phases are stable has been 
reported,16,19,20 the conversion process between these differing co-
crystal phases has not been fully investigated.  50 
 It has been shown for some co-crystal systems that the relative 
stability of co-crystals with differing stoichiometries can be 
altered through the choice of solvent. For example, the benzoic 
acid/isonicotinamide pair has two co-crystals: one with a 1:1 
composition and one with a 2:1 composition.21 Both phases have 55 
been shown to be stable in different aqueous solution 
compositions but only the 1:1 co-crystal is stable in ethanolic 
solutions. This was demonstrated by the addition of crystals of 
the 2:1 phase to a saturated solution, which lead to the complete 
dissolution of the 2:1 crystals in 20 minutes, followed by 60 
crystallisation of the 1:1 phase after 10 hours.13 Understanding 
the balance of stability between the differing phases and the 
choice of solvent is thus required to design suitable conditions for 
the controlled growth of selected phases. Such understanding was 
recently applied to the successful growth of crystals suitable for 65 
single crystal structure determination of the 1:2 malic acid and 
caffeine co-crystal. This malic acid/caffeine system exists in two 
stoichiometries (1:1 and 1:2) and both phases are readily 
obtainable through solid-state grinding. However, only crystals of 
the 1:1 phase suitable for single crystal structure solution could 70 
be obtained by slow evaporation of dichloromethane solution.5 In 
contrast, only poorly diffracting crystals of the 1:2 co-crystal 
could be produced through anti-solvent addition of cyclohexane 
to a saturated 1:2 solution in 15:1 chloroform/methanol mixture. 
Investigations into the relative solubilities of the components 75 
indicated significant differences between the two components for 
the majority of solvents and construction of the ternary phase 
diagram for malic acid/caffeine/acetone indicated that the 1:2 
system was metastable for this system.20 Selection of a solvent 
that reduced the differences in solubility lead to the identification 80 
of a system where both co-crystal phase were stable. Construction 
of the TPD for malic acid/caffeine/ethyl acetate allowed for the 
controlled growth of the 1:2 co-crystal.22 
 For polymorphic systems, solution mediated transformations 
are an important process for the conversion of metastable phases 85 
into stable crystalline phases.23,24 While the general mechanism is 
the dissolution of the metastable phase and regrowth of the stable 
one, these conversions may also occur through heterogeneous 
nucleation driven by an epitaxial interaction between the two 
phases due to similarities in selected surfaces of the two forms.24 90 
For example, the solution mediated transformation of  to  
glutamic acid occurs by nucleation of the  phase on the {111} 
faces of the  phase.25-28 Recently, work in identifying the 
different possible transformation scenarios for polymorph 
transformations has highlighted the balance between dissolution 95 
of the metastable phase and the nucleation and growth of the 
stable phase.29 Similar factors will control the transformation of 
metastable co-crystal phases to stable co-crystal phases, however 
unlike polymorphic systems the stability of a given co-crystal is 
dependant on the composition of the solution. Thus the 100 
transformation process can be easily studied by the addition of 
crystals of one co-crystal into a solution with a composition 
where the other co-crystal is stable.   
 The system comprising p-toulenesulfonamide (TSA) and 
triphenylphosphine oxide (PH3PO) was initially reported to form 105 
as a 3:2 co-crystal30 but subsequent study has identified an 
additional 1:1 co-crystal phase.16 Construction of TPDs in 
acetonitrile and dichloromethane has allowed for the 
identification of distinct solution compositions where each 
individual co-crystal is the thermodynamically stable phase. 110 
Knowledge of these solution compositions allows for preparation 
 
of a solution saturated with respect to one specific co-crystal 
form. This study investigated the behaviour of the 3:2 co-crystal 
of the TSA/ PH3PO system when it was placed in a solution 
saturated with respect to the 1:1 co-crystal, and vice versa. The 
subsequent solution mediated co-crystal transformation was 5 
observed with optical microscopy in real time, and confirmed 
with PXRD on completion.  
 
 
 The saturation concentrations of TSA and  Ph3PO within the 10 
region in acetonitrile solution where the 1:1 and 3:2 co-crystal are 
respectively stable, were initially measured using a Crystal 16TM 
system from Avantium Technologies (Figure 1).† For this system, 
both composition lines for the two co-crystals cross the 1:1 co-
crystal solubility, confirming that the 1:1 co-crystal displays 15 
congruent dissolution, while the 3:2 displays incongruent 
dissolution as shown by the previously determined TPD.16 
 The behaviour of each co-crystal in a solution saturated with 
respect to the other co-crystal respectively was investigated with 
optical microscopy.§ Seed crystals of the 1:1 and 3:2 co-crystal 20 
were produced by heating a 10:20:70 (TSA:Ph3PO:MeCN) and a 
20:10:70 (TSA:Ph3PO:MeCN) mass fraction solution to 60 °C 
and cooling at 0.1 °C/min to 20 °C. The resulting solutions were 
covered with parafilm into which a number of small holes were 
punched to allow evaporation, and left to stand at room 25 
temperature until the crystals increased to a suitable size (3–5 
mm). The seed crystals were placed in 5 ml of saturated solution 
in a temperature controlled optical cell at 20 °C, and a 
microscope image taken every 15 seconds. The 3:2 co-crystal was 
placed in a solution containing 0.20 mol·dm-3 TSA and 0.15 30 
mol·dm-3 Ph3PO (Figure 1, green x), and the 1:1 co-crystal in a 
solution containing 0.56 mol·dm-3 TSA and 0.08 mol·dm-3 Ph3PO 
(Figure 1, red x).  
 
Figure 1: Solubility diagram for TSA/Ph3PO in acetonitrile. The 35 
experimental compositions studied are indicated by the green and red 
crosses.   
 The 3:2 crystal undergoes dissolution initially, and additional 
crystals appear independently of the seed crystal (Figure 2). 
Growth of the new crystals continued until all the seed phase had 40 
dissolved. PXRD of the resulting phase confirmed that the 
crystals were the 1:1 co-crystal (Figure 4).  
 
During the conversion of the 1:1 crystal, the newly formed 
crystals cluster closely around the seed crystal and may be 45 
associated with the dissolving surface (Figure 3). As each 
experiment is undertaken without stirring, a local increase in the 
supersaturation level surrounding the dissolving crystal may 
occur. This would increase the probability of nucleation and 
results in the growth of the expected phase in the vicinity of the 50 
seed crystal. The final product in this case was confirmed as the 
3:2 co-crystal using PXRD. 
 
Figure 2: Solution mediated transformation of the 3:2 co-crystal into the 
1:1 co-crystal in MeCN. Each image represents a time lapse of 10 55 
minutes. The starting crystal was approximately 4 mm in its longest 
dimension.  
 
Figure 3: Solution mediated transformation of the 1:1 co-crystal into the 
3:2 co-crystal in MeCN. Each image represents a time lapse of 20 60 
minutes. The starting crystal was approximately 4 mm in its longest 
dimension.  
 
 
Figure 4. PXRD of 3:2 single crystal which was equilibrated in MeCN 
saturated with the 1:1 co-crystal and the product of this equilibration. 
Reference pattern for the two co-crystals are also included. 
 
Figure 5. PXRD of 1:1 single crystal which was equilibrated in MeCN 5 
saturated with the 3:2 co-crystal and the product of this equilibration. 
Reference pattern for the two co-crystals are also included. 
 The recorded images do not clearly define if heterogeneous 
nucleation occurred on the surface of the co-crystal. As the seed 
crystals are poorly formed, the habits of the crystals have not 10 
been characterised and so identification of the molecular features 
on each surface preventing such interactions is limited. However, 
prediction of the morphology by BFDH gives qualitatively 
similar results to the experimental shapes (Figures 6, 7). From the 
predicted morphologies, the 1:1 co-crystal is bounded by 15 
predominately aromatic functionalities (Figure 6), while the 3:2 
co-crystal has an even mixture of aromatic and sulfonamide 
functional group present on the surfaces (Figure 7). Thus the 
dominant faces of the two phases lack complementary surfaces 
and the potential for strong directional interactions to direct a 20 
surface to surface interaction as observed in the epitaxially driven 
polymorphic transformations.23 Lattice matching calculations 
using epicalc31 also indicate that there is no lattice registry 
between the predicted dominant faces of either phase.  
 25 
Figure 6. BFDH predicted morphology for the 1:1 co-crystal showing the 
molecular packing and indexing of selected crystal faces. 
 
Figure 7. BFDH predicted morphologies for the 3:2 co-crystal showing 
the molecular packing and indexing of selected crystal faces. 30 
Conclusions 
The solution mediated transformation between two co-crystal 
phases has been demonstrated for the p-
toulenesulfonamide/triphenylphosphine oxide system in 
acetonitrile. In this system no surface interaction appears to occur 35 
between the dissolving metastable phase and the growing stable 
phase, unlike many transformations observed for polymorphic 
systems. This may be due to the differences in surface chemistry 
of the two phases and suitable epitaxial interactions cannot be 
formed in this case. This result indicates the importance of 40 
understanding co-crystal stability when attempting to isolate a 
desired co-crystal form.  
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† Experiments were performed on a 1 ml scale. Mass fractions, on a total 
mass basis, were selected to represent regions in the TPD where the 3:2 
co-crystal or the 1:1 co-crystal are independently stable as indicated in the 
previously determined ternary phase diagram. The solutions were held at 55 
60 °C for 1 hour to ensure complete dissolution and subsequently cooled 
at 1 °C/min to 20 °C, and aged for 1 hour. The resulting solids were 
filtered and analysed with powder X-ray diffraction for phase 
composition. Reference PXRD patterns for the 3:2 and 1:1 co-crystal 
were generated from their respective crystallographic information files 60 
(CIF) using Mercury 2.4. 
§ Optical microscopy was performed using a Zeiss Axioplan 2 polarizing 
microscope and the Linksys image capture software. 
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